Literature DB >> 7356933

Preparation and properties of bovine factor VIII (antihemophilic factor).

G A Vehar, E W Davie.   

Abstract

Factor VIII has been purified approximately 300000-fold from bovine plasma by ammonium sulfate fractionation, glycine precipitation, DEAE-Sephadex column chromatography, sulfate--Sepharose column chromatography, Sephadex G-200 gel filtration, and factor X--Sepharose column chromatography. The highly purified preparation migrated as a triplet on sodium dodecyl sulfate/urea--polyacrylamide gel electrophoresis with apparent molecular weights of 93000, 88000, and 85000. The coagulant activity of the purified preparations was inhibited by antibodies raised in rabbits against either the purified factor VIII protein or a preparation of factor VIII/von Willebrand factor. Antibodies to the purified protein also inhibited the coagulant activity of factor VIII/von Willebrand factor preparations. The purified factor VIII contained no platelet-aggregating activity, as measured in human platelet-rich plasma. The purified preparation of factor VIII was required for the activation of factor X in the presence of factor IXa, calcium, and phospholipid. It was activated about 30-fold by thrombin or factor Xa plus calcium and phospholipid, and each of these reactions was accompanied by a change in the sodium dodecyl sulfate/urea--polyacrylamide gel electrophoresis pattern of the protein. Factor VIII was rapidly inactivated by bovine-activated protein C in a reaction requiring calcium and phospholipid. This reaction was also associated with a change in the sodium dodecyl sulfate/urea--polyacrylamide gel electrophoresis pattern of the highly purified protein. These experiments involving three highly specific serine proteases support the conclusion that the triplet observed on polyacrylamide gels is factor VIII.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356933     DOI: 10.1021/bi00544a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  73 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 3.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 4.  The protein C pathway and pathologic processes.

Authors:  F J Castellino; V A Ploplis
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

5.  The characterization of mice with a targeted combined deficiency of protein c and factor XI.

Authors:  J C Chan; J G Ganopolsky; I Cornelissen; M A Suckow; M J Sandoval-Cooper; E C Brown; F Noria; D Gailani; E D Rosen; V A Ploplis; F J Castellino
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  beta-Hydroxyaspartic acid in vitamin K-dependent protein C.

Authors:  T Drakenberg; P Fernlund; P Roepstorff; J Stenflo
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

7.  Free fatty acids inhibit TM-EPCR expression through JNK pathway: an implication for the development of the prothrombotic state in metabolic syndrome.

Authors:  Wanmu Xie; Zhenguo Zhai; Yuanhua Yang; Tuguang Kuang; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

8.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  LPS-Toll-Like Receptor-Mediated Signaling on Expression of Protein S and C4b-Binding Protein in the Liver.

Authors:  Tatsuya Hayashi; Koji Suzuki
Journal:  Gastroenterol Res Pract       Date:  2010-08-18       Impact factor: 2.260

10.  Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

Authors:  W M Canfield; W Kisiel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.